Scarica l'app Stockscreener
67.10
1.49%
-1.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Dexcom Inc Borsa (DXCM) Ultime notizie
DexCom (DXCM) Slid on Poor Execution and GLP-1 Drug Disruption Concerns - Insider Monkey
Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems - Business Wire
DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes - Yahoo Finance
UniSuper Management Pty Ltd Sells 76,404 Shares of DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
DXCM ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders Who Lost Money - ACCESS Newswire
DexCom Stock Price | DXCM Stock Quote, News, and History - Markets Insider
Newly public Beta Bionics reports sales surge; Dexcom hires CCO - MedTech Dive
Sensor Patch Market Size is Expected to Reach $56.4 Billion by 2032 | DexCom,, Medtronic PLC - openPR.com
DexCom Inc. stock underperforms Thursday when compared to competitors - MSN
DexCom, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsDXCM - ACCESS Newswire
Dexcom rejects claims of unauthorized device changes in FDA warning letter - medtechdive.com
DexCom's Options: A Look at What the Big Money is Thinking - Benzinga
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval - Zacks Investment Research
Form DEF 14A DEXCOM INC For: May 08 - StreetInsider
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
FDA says changes in Dexcom G6, G7 sensors constitute misbranding - BioWorld MedTech
DXCM Stock Falls As FDA Warnings Raise Concern For 15-Day G7 Approval - Barchart
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor - MSN
Dexcom’s FDA warning letter reveals unauthorized changes to sensors - medtechdive.com
DXCM Stock Gains Following New Data On Upcoming G7 CGM Sensor - Barchart.com
Dexcom Appoints Jon Coleman as Chief Commercial Officer - BioSpace
DexCom, Inc. (DXCM) Announces Change in Independent Auditors - GuruFocus
DexCom names Jon Coleman as new chief commercial officer By Investing.com - Investing.com South Africa
DexCom appoints Deloitte as new auditor, replacing EY By Investing.com - Investing.com South Africa
DexCom appoints Deloitte as new auditor, replacing EY - Investing.com India
DexCom Names Jon Coleman as Chief Commercial Officer - Marketscreener.com
DexCom names Jon Coleman as new chief commercial officer - Investing.com India
FDA warns Dexcom over continuous glucose monitor testing - Modern Healthcare
Dexcom Appoints Jon Coleman As Chief Commercial Officer - Marketscreener.com
Healthcare Pioneer Dexcom Taps 30-Year Industry Leader to Drive Global Growth - Stock Titan
Citi maintains Buy rating on DexCom stock with $104 target By Investing.com - Investing.com UK
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom - 01Net
A unique opportunity to say thank you - The Persistent Pursuit
Dexcom COO on 15-day glucose sensor, Type 2 coverage - medtechdive.com
DexCom (DXCM): 3 Reasons We Love This Stock - Yahoo Finance
DexCom Faces Short-Term Challenges, But Market Growth Prospects Remain Strong: Analyst - MSN
Is DexCom Gaining or Losing Market Support? - Benzinga
Dexcom shares 15-day CGM data; Tandem posts Type 2 pivotal data - MedTech Dive
Dexcom director Heller sells $24,756 in stock By Investing.com - Investing.com Canada
Dexcom director Heller sells $24,756 in stock - Investing.com
DexCom Inc. stock outperforms competitors on strong trading day - MSN
Dexcom Welcome Renée Galá to its Board of Directors - Medical Product Outsourcing
Buy, Sell, Or Hold DXCM Stock At $70? - Forbes
Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care - 01Net
Dexcom's Game-Changing CGM Achieves Industry-Best 8.0% MARD, Doctors Choose Tech Over Drugs - StockTitan
DexCom, Inc. (DXCM): Among the Best Diabetes Stocks to Buy According to Billionaires - Yahoo Finance
Insulet's Game-Changing Automated Insulin System Expands Global Reach to Australia, Belgium, Canada - StockTitan
74,737 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by Proficio Capital Partners LLC - Defense World
Dexcom’s chief legal officer sells $914,941 in stock By Investing.com - Investing.com Australia
Dexcom CFO sells shares for over $844,000 By Investing.com - Investing.com Australia
Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management - Business Wire
10 Best Diabetes Stocks To Buy According to Billionaires - Insider Monkey
Dexcom EVP Jacob Steven Leach sells stock for $990,670 By Investing.com - Investing.com Australia
Dexcom’s chief legal officer sells $914,941 in stock - Investing.com
0.39%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):